Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology
- 282 Downloads
While we may not be able to find a cure for Alzheimer’s disease (AD) in the near future, several drugs presently in trials have shown promise as possible modifiers of disease progression. However, we may not be able to demonstrate efficacy due to issues of recruitment, retention, site-to-site variability, and other methodological issues. It is thus incumbent on the scientific community to find solutions to these problems, particularly as the field moves toward preventing illness or treating the disease in its prodromal stages, where these methodological issues will become even more critical. We need to better understand why participants agree or refuse to enter drag trials, and why both primary care physicians and Alzheimer’s specialists agree or refuse to involve their patients. We also need to quantify the impact of requiring imaging studies, extensive questionnaires, cognitive testing, and lumbar punctures on recruitment and retention. With these concerns in mind, an international task force meeting of experts from academia and industry in the United States, European Union, and Japan in San Diego, California on November 2, 2011 to focus on recruitment, retention and other methodological issues related to clinical trials for AD. Based on the recommendations of this Task force meeting, this Perspectives article critically reflects on the most critical and timely methodological issues related to recruitment and retention in prevention and therapeutic trials in AD, which are paralleled by a paradigm shift in the diagnostic conceptualization of this disease, as reflected by recently new proposed diagnostic criteria involving preclinical stages of the disease.
Key wordsAlzheimer’s disease biomarkers neuroimaging
Unable to display preview. Download preview PDF.
- 5.Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7: 270–279.PubMedCrossRefGoogle Scholar
- 6.Jack CR, Jr, Albert M, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to revised criteria for the diagnosis of Alzheimer’s disease: National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 7: 257–262.PubMedCrossRefGoogle Scholar
- 7.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 7: 263–269.PubMedCrossRefGoogle Scholar
- 8.Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 7: 280–292.PubMedCrossRefGoogle Scholar
- 10.Schneider LS: Recruitment methods for United States Alzheimer disease prevention trials. J Nutr Health Aging. In Press (2012).Google Scholar
- 16.Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD, et al (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.PubMedCrossRefGoogle Scholar
- 27.Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 7: 367–385.PubMedCrossRefGoogle Scholar
- 28.Donohue MC, Aisen P (2012) Profile models versus slope models for assessing longitudinal change in Alzheimer’s disease clinical trials. J Nutr Health Aging. In Press.Google Scholar
- 29.European Medicines Agency CHMP (2010) Guidelines on Missing Data in Confirmatory Clinical Trials. London, United Kingdom.Google Scholar
- 30.National Research Council Panel on Handling Missing Data in Clinical Trials (2010) The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press, Washington.Google Scholar
- 32.Hampel H, Prvulovic D (2012) Are biomarkers harmful to recruitment and retention in Alzheimer’s disease clinical trials? An international perspective. J Nutr Health Aging. In Press.Google Scholar